Abbott Laboratories (ABT) Aandelenoverzicht
Abbott Laboratories ontdekt, ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen wereldwijd producten voor de gezondheidszorg. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
ABT Community Fair Values
Create NarrativeSee what 261 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$113.88
FV
21.3% ondergewaardeerd intrinsieke korting6.57%
Revenue growth p.a.
223
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Abbott Laboratories Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$89.65 |
| 52 Week Hoogtepunt | US$139.06 |
| 52 Week Laag | US$81.97 |
| Bèta | 0.62 |
| 1 maand verandering | 6.28% |
| 3 maanden verandering | -17.01% |
| 1 Jaar Verandering | -34.30% |
| 3 jaar verandering | -14.64% |
| 5 jaar verandering | -19.69% |
| Verandering sinds IPO | 24,380.42% |
Recent nieuws en updates
Seeking Alpha • Jun 10
Abbott Laboratories: A Better Than 5 Years Ago - But Still Not A Buy
Summary Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income and EPS declined year-over-year. The $21B Exact Sciences acquisition boosts diagnostics growth potential but increases debt and will dilute EPS for two years. Despite solid growth drivers and a robust dividend, high goodwill and elevated debt warrant caution on aggressive capital returns. Read the full article on Seeking Alpha
Narratiefupdate • Jun 02
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.Recent updates
Seeking Alpha • Jun 10
Abbott Laboratories: A Better Than 5 Years Ago - But Still Not A Buy
Summary Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income and EPS declined year-over-year. The $21B Exact Sciences acquisition boosts diagnostics growth potential but increases debt and will dilute EPS for two years. Despite solid growth drivers and a robust dividend, high goodwill and elevated debt warrant caution on aggressive capital returns. Read the full article on Seeking AlphaNarratiefupdate • Jun 02
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.Narratiefupdate • May 12
ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.Narratiefupdate • Apr 23
ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.Narratiefupdate • Apr 09
ABT: AF Portfolio And Dividend Track Record Will Support Future Upside
Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.Narratiefupdate • Mar 26
ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside
Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.Narratiefupdate • Mar 11
ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside
Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.Narratiefupdate • Feb 24
ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside
Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.Narratiefupdate • Feb 10
ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside
Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.Narratiefupdate • Jan 26
ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential
Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.Narratiefupdate • Jan 11
ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside
Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.Analyseartikel • Jan 03
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Narratiefupdate • Dec 27
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns
Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.Narratiefupdate • Dec 12
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside
Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.Narratiefupdate • Nov 28
ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside
Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.Narratiefupdate • Nov 14
ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains
Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.Analyseartikel • Nov 05
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Narratiefupdate • Oct 31
ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead
Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.Narratiefupdate • Oct 16
Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds
Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.Analyseartikel • Sep 15
There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...Seeking Alpha • Apr 16
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking AlphaSeeking Alpha • Mar 16
Abbott Laboratories Basking In A Sharp Turn In Sentiment
Summary Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk. Fourth quarter results showed 9% organic revenue growth, with medical devices leading at 14%, and improved profit margins. Abbott's medical device business is executing well, with double-digit growth in structural heart and diabetes, and above-peer results across most of the business. An important legal victory could signal lower overall risk in its infant nutrition litigation, while a lackluster trial result from a rival could re-energize the outlook for TriClip. Valuation is more challenging now, as it takes a pretty aggressive bull-case model to find significant fundamentals-driven upside. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ABT | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -1.2% | -0.2% | -2.4% |
| 1Y | -34.3% | -20.7% | 21.5% |
Rendement versus industrie: ABT presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -20.7 % opleverde.
Rendement versus markt: ABT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 21.5 % opleverde.
Prijsvolatiliteit
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: ABT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van ABT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1888 | 115,000 | Robert Ford | www.abbott.com |
Abbott Laboratories ontdekt, ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen wereldwijd producten voor de gezondheidszorg. Het bedrijf is actief in vier segmenten: Farmaceutische Producten, Diagnostische Producten, Voedingsproducten en Medische Hulpmiddelen. Het bedrijf biedt generieke geneesmiddelen voor de behandeling van pancreas exocriene insufficiëntie, prikkelbare darm syndroom of galweg spasme, intrahepatische cholestase of depressieve symptomen, gynaecologische aandoening, hormoonvervangingstherapie, dyslipidemie, hypertensie, hypothyreoïdie, hypertriglyceridemie, de ziekte van Ménière en vestibulaire duizeligheid, pijn, koorts, ontsteking en migraine, en biedt ook het anti-infectiemiddel claritromycine, griepvaccin en producten om het fysiologische ritme van de dikke darm te reguleren.
Abbott Laboratories Samenvatting
| ABT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$155.32b |
| Inkomsten(TTM) | US$6.25b |
| Inkomsten(TTM) | US$45.13b |
25.0x
Koers/Winstverhouding3.5x
P/S-verhoudingIs ABT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ABT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$45.13b |
| Kosten van inkomsten | US$19.63b |
| Brutowinst | US$25.50b |
| Overige uitgaven | US$19.25b |
| Inkomsten | US$6.25b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 3.59 |
| Brutomarge | 56.50% |
| Nettowinstmarge | 13.85% |
| Schuld/Eigen Vermogen Verhouding | 64.8% |
Hoe presteerde ABT op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.8%
Huidig dividendrendement68%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/11 14:56 |
| Aandelenkoers aan het einde van de dag | 2026/06/11 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Abbott Laboratories wordt gevolgd door 51 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |